Is Symbiox Investme overvalued or undervalued?

As of 12 November 2025, the valuation grade for Symbiox Investme has moved from fair to attractive, indicating a more favorable outlook for the company. The company is currently assessed as undervalued, particularly when considering its PE ratio of 36.10, which is relatively high, but its PEG ratio of 0.23 suggests significant growth potential. Additionally, the EV to EBIT and EV to EBITDA ratios are both at -4.38, highlighting a unique valuation scenario that may attract investors.
In comparison to its peers, Symbiox Investme's valuation metrics stand out. For instance, Bajaj Finance, considered very expensive, has a PE ratio of 34.41, while Life Insurance, classified as very attractive, shows a much lower PE of 11.14. This suggests that Symbiox Investme offers a competitive edge in terms of growth potential relative to its valuation. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -44.65% compared to the Sensex's 8.10%, the overall valuation metrics indicate that the company may be a compelling investment opportunity moving forward.